Adjuvant tamoxifen and exemestane in early breast cancer (TEAM): A randomised phase 3 trial

The Lancet

Volumn 377, Issue 9762, 2011, Pages 321-331

  Van De Velde, Cornelis Jh ^a   Rea, Daniel ^b   Seynaeve, Caroline ^c   Putter, Hein ^a   Hasenburg, Annette ^d   Vannetzel, Jean Michel ^e   Paridaens, Robert ^f   Markopoulos, Christos ^g   Hozumi, Yasuo ^h   Hille, Elysee Tm ^a   Kieback, Dirk G ⁱ   Asmar, Lina ^j   Smeets, Jan ^k   Nortier, Johan Wr ^a   Hadji, Peyman ^l   Bartlett, John Ms ^m   Jones, Stephen E ^j  

^a LEIDEN UNIVERSITY MEDICAL CENTER   (Netherlands)

^b UNIVERSITY OF BIRMINGHAM   (United Kingdom)

^c ERASMUS MEDICAL CENTER   (Netherlands)

^d UNIVERSITY OF FREIBURG   (Germany)

^e Institut du Sein Henri Hartmann (ISHH)   (France)

^f UNIVERSITY HOSPITALS LEUVEN   (Belgium)

^g UNIVERSITY OF ATHENS MEDICAL SCHOOL   (Greece)

^h JICHI MEDICAL UNIVERSITY   (Japan)

ⁱ Elblandkliniken   (Germany)

^j Developmental Therapeutics Committee and Co Chair of the Genitourinary Committee   (United States)

^k Pfizer Ltd   (United States)

^l PHILIPPS UNIVERSITY MARBURG   (Germany)

^m UNIVERSITY OF EDINBURGH   (United Kingdom)

more..

Author keywords

[No Author keywords available]

Indexed keywords

EXEMESTANE; TAMOXIFEN;

ADULT; AGED; ARTHROPATHY; ARTICLE; BRAIN INFARCTION; BREAST CANCER; BREAST DISEASE; CANCER ADJUVANT THERAPY; CEREBROVASCULAR ACCIDENT; DEPRESSION; DISEASE FREE SURVIVAL; DIZZINESS; DRUG SAFETY; EARLY CANCER; EMBOLISM; ENDOCRINE DISEASE; ENDOMETRIAL DISEASE; FEMALE; FLUSHING; FRACTURE; GYNECOLOGIC DISEASE; HEART ARRHYTHMIA; HEART DISEASE; HEART FAILURE; HEART INFARCTION; HEART MUSCLE ISCHEMIA; HUMAN; HYPERLIPIDEMIA; HYPERTENSION; INSOMNIA; KIDNEY DISEASE; LIBIDO DISORDER; LIVER FUNCTION TEST; MAJOR CLINICAL STUDY; MENTAL DISEASE; METABOLIC DISORDER; MONOTHERAPY; MULTICENTER STUDY; MUSCLE DISEASE; MUSCULOSKELETAL DISEASE; NERVE COMPRESSION; NEUROLOGIC DISEASE; OSTEOPOROSIS; PERIPHERAL OCCLUSIVE ARTERY DISEASE; PHASE 3 CLINICAL TRIAL; POSTMENOPAUSE; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SIDE EFFECT; SLEEP DISORDER; SWEAT; THROMBOSIS; VAGINA DISCHARGE; VASCULAR DISEASE; VEIN THROMBOSIS; VULVOVAGINAL DISEASE; WEIGHT GAIN;

EID: 78751647876     PISSN: 01406736     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0140-6736(10)62312-4     Document Type: Article

References (32)

1. Early Breast Cancer Trialists' Collaborative Group Tamoxifen for early breast cancer: an overview of the randomised trials. Early Breast Cancer Trialists' Collaborative Group Lancet 351 1998 1451 1467
2. J Bonneterre, A Buzdar, JM Nabholtz Anastrozole is superior to tamoxifen as first-line therapy in hormone receptor positive advanced breast carcinoma Cancer 92 2001 2247 2258
3. H Mouridsen, M Gershanovich, Y Sun Phase III study of letrozole versus tamoxifen as first-line therapy of advanced breast cancer in postmenopausal women: analysis of survival and update of efficacy from the International Letrozole Breast Cancer Group J Clin Oncol 21 2003 2101 2109
4. RJ Paridaens, LY Dirix, LV Beex Phase III study comparing exemestane with tamoxifen as first-line hormonal treatment of metastatic breast cancer in postmenopausal women: the European Organisation for Research and Treatment of Cancer Breast Cancer Cooperative Group J Clin Oncol 26 2008 4883 4890
5. The Arimidex Tamoxifen Alone or in Combination (ATAC) Trialists' Group Effect of anastrozole and tamoxifen as adjuvant treatment for early-stage breast cancer: 100-month analysis of the ATAC trial Lancet Oncol 9 2008 45 53
6. AS Coates, A Keshaviah, B Thurlimann Five years of letrozole compared with tamoxifen as initial adjuvant therapy for postmenopausal women with endocrine-responsive early breast cancer: update of study BIG 1-98 J Clin Oncol 25 2007 486 492
7. RC Coombes, LS Kilburn, CF Snowdon Survival and safety of exemestane versus tamoxifen after 2-3 years' tamoxifen treatment (Intergroup Exemestane Study): a randomised controlled trial Lancet 369 2007 559 570
8. National Comprehensive Cancer Network NCCN clinical practice guidelines in oncology: breast cancer V.1.2010 2010 National Comprehensive Cancer Network Fort Washington, PA
9. A Goldhirsch, JN Ingle, RD Gelber, AS Coates, B Thurlimann, HJ Senn Thresholds for therapies: highlights of the St Gallen International Expert Consensus on the primary therapy of early breast cancer 2009 Ann Oncol 20 2009 1319 1329
10. HJ Burstein, AA Prestrud, J Seidenfeld American Society of Clinical Oncology clinical practice guideline: update on adjuvant endocrine therapy for women with hormone receptor-positive breast cancer J Clin Oncol 28 2010 3784 3796
11. H Mouridsen, A Giobbie-Hurder, A Goldhirsch Letrozole therapy alone or in sequence with tamoxifen in women with breast cancer N Engl J Med 361 2009 766 776
12. L Hughes-Davies, C Caldas, GC Wishart Tamoxifen: the drug that came in from the cold Br J Cancer 101 2009 875 878
13. RC Coombes, E Hall, LJ Gibson A randomized trial of exemestane after two to three years of tamoxifen therapy in postmenopausal women with primary breast cancer N Engl J Med 350 2004 1081 1092 (Pubitemid 38298988)
14. JGH van Nes, C Seynaeve, S Jones Variations in locoregional therapy in postmenopausal patients with early breast cancer treated in different countries Br J Surg 97 2010 671 679
15. SE Jones, J Cantrell, S Vukelja Comparison of menopausal symptoms during the first year of adjuvant therapy with either exemestane or tamoxifen in early breast cancer: report of a Tamoxifen Exemestane Adjuvant Multicenter trial substudy J Clin Oncol 25 2007 4765 4771
16. National Cancer Institute Common toxicity criteria, version 2.0 http://ctep.cancer.gov/protocolDevelopment/electronic-applications/docs/ ctcmanual-v4-10-4-99.pdf (accessed Dec 27, 2010).
17. MedDRA Maintenance and support organization introductory guide, version 12.1 https://meddramsso.com/secure/subscriber-download-v12-1.asp 2009 (accessed Dec 27, 2010).
18. SE Jones, C Seynaeve, A Hasenburg Results of the first planned analysis of the TEAM (tamoxifen exemestane adjuvant multinational) prospective randomized phase III trial in hormone sensitive postmenopausal early breast cancer. 31st annual San Antonio Breast Cancer Symposium, San Antonio, TX, USA, Dec 10-14, 2008: 15 (abstr) http://www.sabcs.org/EnduringMaterials/index.aspslidereview (accessed Dec 28, 2010).
19. SJ Pocock, NL Geller, AA Tsiatis The analysis of multiple endpoints in clinical trials Biometrics 43 1987 487 498
20. H Putter, M Fiocco, RB Geskus Tutorial in biostatistics: competing risks and multi-state models Stat Med 26 2007 2389 2430
21. M Dowsett, J Cuzick, J Ingle Meta-analysis of breast cancer outcomes in adjuvant trials of aromatase inhibitors versus tamoxifen J Clin Oncol 28 2009 509 518
22. M Dowsett, C Allred, J Knox Relationship between quantitative estrogen and progesterone receptor expression and human epidermal growth factor receptor 2 (HER-2) status with recurrence in the Arimidex, Tamoxifen, Alone or in Combination trial J Clin Oncol 26 2008 1059 1065
23. G Viale, MM Regan, E Maiorano Prognostic and predictive value of centrally reviewed expression of estrogen and progesterone receptors in a randomized trial comparing letrozole and tamoxifen adjuvant therapy for postmenopausal early breast cancer: BIG 1-98 J Clin Oncol 25 2007 3846 3852
24. Bartlett JMS, Brookes CL, Billingham LJ, et al. A prospectively planned pathology study within the TEAM trial confirms that progesterone receptor expression is prognostic but is not predictive for differential response to exemestane versus tamoxifen. 31st annual San Antonio Breast Cancer Symposium, San Antonio, TX, USA, Dec 10-14, 2008: 81 (abstr).
25. B Thurlimann, A Keshaviah, AS Coates A comparison of letrozole and tamoxifen in postmenopausal women with early breast cancer N Engl J Med 353 2005 2747 2757
26. Jakesz R, Gnant M, Griel R, et al. Tamoxifen and anastrozole as a sequencing strategy in postmenopausal women with hormone-responsive early breast cancer: updated data from the Austrian breast and colorectal cancer study group trial 8. 31st annual San Antonio Breast Cancer Symposium, San Antonio, TX, USA, Dec 10-14, 2008: 14 (abstr).
27. C Markopoulos, A Polychronis, V Zobolas The effect of exemestane on the lipidemic profile of postmenopausal early breast cancer patients: preliminary results of the TEAM Greek sub-study Breast Cancer Res Treat 93 2005 61 66 (Pubitemid 41355992)
28. C Markopoulos, A Polychronis, U Dafni, D Koukouras, V Zobolas, E Tzorakoleftherakis Lipid changes in breast cancer patients on exemestane treatment: final results of the TEAM Greek substudy Ann Oncol 20 2009 49 55
29. DG Kieback, N Harbeck, W Bauer Endometrial effects of exemestane compared to tamoxifen within the Tamoxifen Exemestane Adjuvant Multicenter (TEAM) trial: results of a prospective gynecological ultrasound substudy Gynecol Oncol 119 2010 500 505
30. P Hadji, M Ziller, DG Kieback Effects of exemestane and tamoxifen on bone health within the Tamoxifen Exemestane Adjuvant Multicentre (TEAM) trial: results of a German, 12-month, prospective, randomised sub-study Ann Oncol 20 2009 203 207
31. S Jones, C Stokoe, M Sborov The effect of tamoxifen or exemestane on bone mineral density during the first 2 years of adjuvant treatment of postmenopausal women with early breast cancer Clin Breast Cancer 8 2008 527 532
32. CM Schilder, C Seynaeve, LV Beex Effects of tamoxifen and exemestane on cognitive functioning of postmenopausal patients with breast cancer: results from the neuropsychological side study of the tamoxifen and exemestane adjuvant multinational trial J Clin Oncol 28 2010 1294 1300